Type 2 Diabetics Get Access To New Once-Daily Medication
The FDA has recently approved a new once daily tablet called Tradjenta to assist type 2 diabetics in controlling their blood sugar. The new medication, whose generic name is linagliptin, is a DPP-4 inhibitor. It can be placed in the same classifications as other drugs such as Onglyza and Januvia.
Medication can also be taken with other diabetes treatments such as metformin. "This approval provides another treatment option for the millions of Americans with type 2 diabetes," Mary Parks, MD, director of the FDA's division of metabolism and endocrinology products, said in a news release. "It is effective when used alone or when added to existing treatment regimens."
The medication blocks a chemical marker in the gut cells which helps create the release of insulin after a meal. This process keeps the blood sugar levels from going up while keeping the user secure from the associated drop in blood sugar known as hypoglycemia.
There are some side effects of the medication such as sore throat, headache, runny nose, stuffy nose, muscle pain and upper respiratory infection. The drug is marketed by Boehringer Ingelheim and Lilly.